NLS Collaboration

Mavatar has announced a research collaboration with the group of Bruno Paiva, Director of Flow Cytometry at Clínica Universidad de Navarra and Principal Investigator of the Translational Immunomics in Hematological Neoplasms Research Group at Cima Universidad de Navarra, Spain.

Alzinova has entered into a non-binding Letter of Intent with Fujirebio, a global provider of in vitro diagnostic solutions, regarding the potential development and commercialization of a blood-based diagnostic test for Alzheimer’s disease based on Alzinova’s Aβ42CC oligomer technology.

The companies have announced a strategic co-development partnership to design and advance a new generation of nanobody therapeutics for cancers of high unmet need.

Scientific excellence in a fragmented market means Europe will either lead or fall behind in global biotech.

The agreement, building on a letter of intent announced earlier this year, is intended to establish a long-term partnership in spray-dried formulations, a technology considered important for the development of inhalable drug formulations for biologics, vaccines, and other large molecules.

A newly approved EUR 2.8 million project will, over the next three years, bring together leading organizations from Sweden, Denmark and Norway to accelerate commercialization, investment and market access for companies developing solutions in women's health.